Abstract
Protection tests using passively administered antibody have been carried out using 2 mouse lymphomata. The classic model (“Gorer System”) used alloantiserum which was absorbed in vivo to make it tumour specific before use. In order to provide a system suitable for our work, the model was changed by stepwise transitions to tumour specific immunoglobulin made from xenoantiserum absorbed in vitro, since such a procedure is also applicable to human patients. The time lapse used between challenge and treatment in the allo-system was generally ± 2 h but in the xeno-system could be extended to + 18 h. The xenoantisera could not be absorbed in vivo but required 3 to 5 × 103 spleens per 100 ml serum to absorb in vitro to render them tumour specific. The protective antibody was in the IgG (not IgM) fraction of serum. Maximal tumour specific antibody (measured by in vivo protection) appeared after the third injection of rabbits for one lymphoma, but after the fifth for another. The sera were not cross-reactive among 3 lymphomata tested, of which 2 were of the same H-2 genotype.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Albert W. H., Davies D. A. H-2 antigens on nuclear membranes. Immunology. 1973 May;24(5):841–850. [PMC free article] [PubMed] [Google Scholar]
- DAVIES D. A. OCCURRENCE OF X ANTIGENIC SPECIFICITY IN HISTOCOMPATIBILITY ANTIGENS PREPARED FROM MOUSE LEUKAEMIC CELLS. Br J Exp Pathol. 1963 Oct;44:546–550. [PMC free article] [PubMed] [Google Scholar]
- Davies D. A., Buckham S., Manstone A. J. Protection of mice against syngeneic lymphomata: II. Collaboration between drugs and antibodies. Br J Cancer. 1974 Oct;30(4):305–311. doi: 10.1038/bjc.1974.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Davies D. A. Mouse histocompatibility isoantigens derived from normal and from tumour cells. Immunology. 1966 Aug;11(2):115–125. [PMC free article] [PubMed] [Google Scholar]
- Davies D. A., O'Neill G. J. In vivo and in vitro effects of tumour specific antibodies with chlorambucil. Br J Cancer Suppl. 1973 Aug;1:285–298. [PMC free article] [PubMed] [Google Scholar]
- GORER P. A., AMOS D. B. Passive immunity in mice against C57BL leukosis E.L. 4 by means of iso-immune serum. Cancer Res. 1956 May;16(4):338–343. [PubMed] [Google Scholar]
- Leclerc J. C., Levy J. P., Varet B., Oppenheim S., Senik A. Antigenic analysis of L strain cells: a new murine leukemia-associated antigen, "L". Cancer Res. 1970 Jul;30(7):2073–2079. [PubMed] [Google Scholar]
- Old L. J., Stockert E., Boyse E. A., Kim J. H. Antigenic modulation. Loss of TL antigen from cells exposed to TL antibody. Study of the phenomenon in vitro. J Exp Med. 1968 Mar 1;127(3):523–539. doi: 10.1084/jem.127.3.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rowland G. F., Edwards A. J., Hurd C. M., Sumner M. R. Changes in lymphoreticular tissues during growth of a murine adenocarcinoma. 3. Plaque-forming cell response in lymph nodes and spleen. J Natl Cancer Inst. 1971 Aug;47(2):321–327. [PubMed] [Google Scholar]